MedTrace Logo

Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers

NCT02551744 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2019-08-08

Study results available
· View outcomes & findings →

Summary

Whether pantoprazole versus famotidine for the prevention of recurrent peptic ulcers in thienopyridine users remains unclear.

Conditions

  • Peptic Ulcer

Interventions

DRUG

histamine-2 receptor antagonist group

famotidine tab 40 mg qd for 6 months.

DRUG

proton pump inhibitor group

pantoprazole tab 40 mg qd for 6 months.

Sponsors & Collaborators

  • Kaohsiung Veterans General Hospital.

    lead OTHER

Principal Investigators

  • Ping-I Hus, Bachelor · Kaohsiung Veterans General Hospital.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02551744 on ClinicalTrials.gov